MA54520A - Composés anticancéreux - Google Patents

Composés anticancéreux

Info

Publication number
MA54520A
MA54520A MA054520A MA54520A MA54520A MA 54520 A MA54520 A MA 54520A MA 054520 A MA054520 A MA 054520A MA 54520 A MA54520 A MA 54520A MA 54520 A MA54520 A MA 54520A
Authority
MA
Morocco
Prior art keywords
anticancer compounds
anticancer
compounds
Prior art date
Application number
MA054520A
Other languages
English (en)
Other versions
MA54520B1 (fr
Inventor
López Patricia Gema Cruz
Marchante Maria Del Carmen Cuevas
Solloso Andrés M Francesch
López María Jesús Martín
Acebes Raquel Rodríguez
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of MA54520A publication Critical patent/MA54520A/fr
Publication of MA54520B1 publication Critical patent/MA54520B1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26Acyclic or carbocyclic radicals, substituted by hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/661Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/08Esters of oxyacids of phosphorus
    • C07F9/141Esters of phosphorous acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/24Heterocyclic radicals containing oxygen or sulfur as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MA54520A 2018-12-17 2019-12-17 Composés anticancéreux MA54520B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18382934 2018-12-17
PCT/EP2019/085544 WO2020127194A1 (fr) 2018-12-17 2019-12-17 Composés anticancéreux

Publications (2)

Publication Number Publication Date
MA54520A true MA54520A (fr) 2022-03-23
MA54520B1 MA54520B1 (fr) 2023-09-27

Family

ID=64746491

Family Applications (1)

Application Number Title Priority Date Filing Date
MA54520A MA54520B1 (fr) 2018-12-17 2019-12-17 Composés anticancéreux

Country Status (34)

Country Link
US (1) US20220056021A1 (fr)
EP (1) EP3898613B1 (fr)
JP (1) JP7525493B2 (fr)
KR (1) KR20210104791A (fr)
CN (1) CN113166102A (fr)
AR (1) AR116911A1 (fr)
AU (1) AU2019400736A1 (fr)
BR (1) BR112021011304A2 (fr)
CA (1) CA3123744A1 (fr)
CL (1) CL2021001584A1 (fr)
CO (1) CO2021009339A2 (fr)
DK (1) DK3898613T3 (fr)
EA (1) EA202191714A1 (fr)
EC (1) ECSP21050732A (fr)
ES (1) ES2961370T3 (fr)
FI (1) FI3898613T3 (fr)
HR (1) HRP20231286T1 (fr)
HU (1) HUE064529T2 (fr)
IL (1) IL284011B1 (fr)
JO (1) JOP20210139A1 (fr)
LT (1) LT3898613T (fr)
MA (1) MA54520B1 (fr)
MD (1) MD3898613T2 (fr)
MX (1) MX2021007276A (fr)
PH (1) PH12021551438A1 (fr)
PL (1) PL3898613T3 (fr)
PT (1) PT3898613T (fr)
RS (1) RS64727B1 (fr)
SG (1) SG11202105992SA (fr)
SI (1) SI3898613T1 (fr)
TW (1) TWI830837B (fr)
UY (1) UY38516A (fr)
WO (1) WO2020127194A1 (fr)
ZA (1) ZA202104675B (fr)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR320701A0 (en) 2001-02-20 2001-03-15 Kim, Jonghee The new cancer therapeutic agent with a thiopeptides
AU2004263509A1 (en) 2003-08-08 2005-02-17 Merck Sharp & Dohme Corp. Tetrahydropyran heterocyclic cyclopentyl heteroaryl modulators of chemokine receptor activity
GB0523098D0 (en) * 2005-11-14 2005-12-21 Pharma Mar Sa Antitumoral compounds
AU2008317352A1 (en) * 2007-10-24 2009-04-30 Merck Sharp & Dohme Corp. Heterocycle amide T-type calcium channel antagonists
MX2011012712A (es) * 2009-05-29 2012-01-30 Raqualia Pharma Inc Derivados de carboxamida sustituidos con arilo como bloqueadores del canal de calcio o sodio.

Also Published As

Publication number Publication date
HRP20231286T1 (hr) 2024-02-02
CN113166102A (zh) 2021-07-23
CL2021001584A1 (es) 2021-11-26
AR116911A1 (es) 2021-06-23
UY38516A (es) 2020-07-31
KR20210104791A (ko) 2021-08-25
SG11202105992SA (en) 2021-07-29
CO2021009339A2 (es) 2021-09-30
WO2020127194A1 (fr) 2020-06-25
AU2019400736A1 (en) 2021-07-22
US20220056021A1 (en) 2022-02-24
EP3898613B1 (fr) 2023-08-09
ECSP21050732A (es) 2021-08-31
EP3898613A1 (fr) 2021-10-27
HUE064529T2 (hu) 2024-04-28
JP7525493B2 (ja) 2024-07-30
PL3898613T3 (pl) 2023-12-27
EA202191714A1 (ru) 2022-03-05
MA54520B1 (fr) 2023-09-27
PT3898613T (pt) 2023-10-17
TWI830837B (zh) 2024-02-01
IL284011A (en) 2021-08-31
TW202039475A (zh) 2020-11-01
JP2022513268A (ja) 2022-02-07
ZA202104675B (en) 2023-12-20
ES2961370T3 (es) 2024-03-11
LT3898613T (lt) 2023-09-25
MD3898613T2 (ro) 2023-12-31
BR112021011304A2 (pt) 2021-08-31
CA3123744A1 (fr) 2020-06-25
PH12021551438A1 (en) 2021-12-06
IL284011B1 (en) 2024-08-01
JOP20210139A1 (ar) 2023-01-30
SI3898613T1 (sl) 2023-12-29
RS64727B1 (sr) 2023-11-30
FI3898613T3 (fi) 2023-11-02
MX2021007276A (es) 2021-07-15
DK3898613T3 (da) 2023-11-13

Similar Documents

Publication Publication Date Title
MA49701A (fr) Composés immunomodulateurs
MA52421A (fr) Composés pharmaceutiques
MA52948A (fr) Composés
MA52560A (fr) Composés hétéroaryles tétracycliques
MA52489A (fr) Nouveaux composés
MA47131A (fr) Composés benzyl-amide phosphodiamide antiviraux
MA51669A (fr) Composés
MA44233A (fr) Nouveaux composés
DK4065575T3 (da) Substituerede tricycliske forbindelser
MA42293A (fr) Composés antibactériens
MA53003A (fr) Composés
MA44050A (fr) Nouveaux composés
MA41614A (fr) Composés antiviraux
DK3810587T3 (da) Substituerede alkoxypyridinylindolsulfonamider
ES2982030T3 (es) Compuesto multiaziridínico
DK4039675T3 (da) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl forbindelser
MA44020A (fr) Composés antitumoraux
MA45221A (fr) Nouveaux composés antibactériens
MA49621A (fr) Composés bifonctionnels
MA50504A (fr) Composés antibactériens
MA49522A (fr) Nouveaux composés de quinoléinone
MA49623A (fr) Composés chimiques
MA42034A (fr) Composés pipéridiniques tricycliques
MA52946A (fr) Composés
MA53430A (fr) Nouveaux composés